Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2009

Institut Pasteur and Mérieux Alliance Sign Letter of Intent

Institut Pasteur and Mérieux Alliance Sign Letter of Intent

Collaboration to promote research on infectious disease planned

  • The Institut Pasteur and Mérieux Alliance signed a letter of intent to form a long-term partnership to conduct research in the field of infectious disease. Research topics will include food safety, clinical diagnostics, and immunotherapy.

    The results of the collaboration could be utilized by the various Mériux Alliance companies in products, and would become part of the Institut Pasteur's patent portfolio, according to a statement.

    Mérieux Alliance consists of five public health companies: bioMérieux, Silliker, Shantha Biotechnics, Transgene, and Advanced Bioscience Laboratories.

    "I am extremely pleased with this agreement with Mérieux Alliance that will contribute to improving public health worldwide," says Alice Dautry, president of the Institut Pasteur. "Together, we want to develop innovative approaches that will allow us, in the future, to win new battles against disease."

    The letter follows an agreement signed April 14th between the Institut Pasteur and the Fondation Mérieux to work together on controlling infectious disease in developing countries.ADNFCR-2184-ID-19174395-ADNFCR



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »